Change in Patient-repOrted Outcomes in COPD Patients Newly Initiated on TRIXEO AEROSPHERE in Real worlD - Trial NCT06368427
Access comprehensive clinical trial information for NCT06368427 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Not yet recruiting. The study focuses on Chronic Obstructive Pulmonary Disease (COPD). Target enrollment is 250 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
budesonide / glycopyrronium / formoterol
Observational
drug
Sponsor & Location
AstraZeneca
Timeline & Enrollment
N/A
Apr 30, 2024
Sep 30, 2025
Primary Outcome
Change from baseline to 12 weeks (3 months) in the COPD Assessment Test (CAT) score
Summary
The purpose of this study is to describe patients' clinical and self-reported outcomes of
 treatment with budesonide / glycopyrronium / formoterol Metered dose inhaler (BGF MDI) in
 Romania in real-life setting, up to 6 month of observation period. The study will focus
 primarily on the change in self-perceived health status in the first 12 weeks (3 months) of
 treatment with no pre-defined hypothesis.
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06368427
Non-Device Trial